Biologics and Sublingual Immunotherapy

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

March 1, 2028

Conditions

Asthma, Allergic

Interventions

BIOLOGICAL

omalizumab

adding omalizumab to anti asthmatic therapy

All Listed Sponsors

collaborator

Centrum Medyczne Andrzej Bożek

UNKNOWN

lead

Medical University of Silesia

OTHER

NCT06027073 - Biologics and Sublingual Immunotherapy | Biotech Hunter | Biotech Hunter